SUMMARY
Radium-223 is a targeted alpha therapy, which has a unique mechanism of action and is
used for the treatment of mCRPC with bone metastases
3–5
The spread of prostate cancer into the bone is a critical step in disease progression to
metastatic prostate cancer
1,2
Radium-223 in combination with best standard of care significantly extends overall survival
in patients with mCRPC without visceral metastases
6
There is a well-defined window of opportunity to introduce radium-223 in patients with mCRPC
The majority of patients with mCRPC are eligible for radium-223 treatment and should
receive early radium-223 following disease progression on first-line anti-hormonal
therapy
Radium-223 should be administered for the full 6 cycles unless patients experience significant
and confirmed disease progression
6,7
1.
Pezaro CJ
et al. Eur Urol
2014;65:270–273.
2.
Gundem G
et al. Nature
2015; 520(7547):353–357.
3.
Henriksen G
et al. Cancer Res
2002;62:3120–3125.
4.
Bruland OS
et al. Clin Cancer Res
2006;12:6250s–6257s.
5.
Suominen MI
et al.
Presented at: AACR 2015. Poster 3447.
6.
Parker C
et al. N Engl J Med
2013;369(3):213–223.
